ES2498521A1 - Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad - Google Patents

Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad Download PDF

Info

Publication number
ES2498521A1
ES2498521A1 ES201330233A ES201330233A ES2498521A1 ES 2498521 A1 ES2498521 A1 ES 2498521A1 ES 201330233 A ES201330233 A ES 201330233A ES 201330233 A ES201330233 A ES 201330233A ES 2498521 A1 ES2498521 A1 ES 2498521A1
Authority
ES
Spain
Prior art keywords
nanoemulsions
formulations based
treating obesity
pharmaceuticals
acylethanolamines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201330233A
Other languages
English (en)
Other versions
ES2498521B1 (es
Inventor
Fernando Rodriguez de Fonseca
Francisco Javier PAVÓN MORÓN
Antonia SERRANO CRIADO
Miguel Romero Cuevas
Miguel WULFF PÉREZ
María José GÁLVEZ RUIZ
Antonio MARTÍN RODRÍGUEZ
Juan DE VICENTE ÁLVAREZ-MANZANEDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Granada
Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (Fundacion Imabis)
Original Assignee
Universidad de Granada
Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (Fundacion Imabis)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Granada, Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (Fundacion Imabis) filed Critical Universidad de Granada
Priority to ES201330233A priority Critical patent/ES2498521B1/es
Priority to EP14754920.8A priority patent/EP2985276A4/en
Priority to PCT/ES2014/070129 priority patent/WO2014128333A1/es
Publication of ES2498521A1 publication Critical patent/ES2498521A1/es
Application granted granted Critical
Publication of ES2498521B1 publication Critical patent/ES2498521B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad. La presente invención es de interés para el sector farmacéutico. Se refiere a nuevas formulaciones terapéuticas basadas en nanoemulsiones de aceites vegetales como sistema transportador de fármacos derivados de N-aciletanolaminas (NAEs) para su administración como herramienta farmacológica y como fármacos para la inducción de saciedad y control de la ingesta, modulación de los efectos metabólicos proanorexígenos y prevención de ganancia de peso.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
    imagen7
    imagen8
ES201330233A 2013-02-20 2013-02-20 Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad Expired - Fee Related ES2498521B1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES201330233A ES2498521B1 (es) 2013-02-20 2013-02-20 Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
EP14754920.8A EP2985276A4 (en) 2013-02-20 2014-02-20 Formulations based on nanoemulsions and the use thereof for treating obesity
PCT/ES2014/070129 WO2014128333A1 (es) 2013-02-20 2014-02-20 Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330233A ES2498521B1 (es) 2013-02-20 2013-02-20 Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad

Publications (2)

Publication Number Publication Date
ES2498521A1 true ES2498521A1 (es) 2014-09-24
ES2498521B1 ES2498521B1 (es) 2015-08-18

Family

ID=51390540

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330233A Expired - Fee Related ES2498521B1 (es) 2013-02-20 2013-02-20 Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad

Country Status (3)

Country Link
EP (1) EP2985276A4 (es)
ES (1) ES2498521B1 (es)
WO (1) WO2014128333A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
US10653666B1 (en) 2020-01-14 2020-05-19 King Abdulaziz University Cardioprotective nano-pharmaceutical formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
DE69535127T2 (de) * 1994-03-18 2007-02-15 Supernus Pharmaceuticals, Inc. Emulgierte arzneistoffabgabesysteme
JP4817495B2 (ja) * 1998-05-29 2011-11-16 ニューロサイエンシーズ・リサーチ・ファウンデーション・インコーポレーテッド 外因性カンナビノイドでの痛みの制御
KR20030087657A (ko) * 2001-03-27 2003-11-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 체지방 감소 및 지방산 대사 조절을 위한 방법, 화합물 및조성물
DE10217131A1 (de) * 2001-07-31 2003-02-13 Kuhs Kosmetik Gmbh & Co Kg Topisch applizierbare Zusammensetzung sowie Werkstoffgemisch
US8449867B2 (en) * 2004-08-31 2013-05-28 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
EP2091523A1 (en) * 2006-10-05 2009-08-26 DSMIP Assets B.V. Anandamide
ATE513027T1 (de) * 2008-04-02 2011-07-15 Nestec Sa Funktionelle mesophasen auf oleylethanolamidbasis
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
CA2840965C (en) * 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions

Also Published As

Publication number Publication date
WO2014128333A1 (es) 2014-08-28
EP2985276A4 (en) 2017-01-25
EP2985276A1 (en) 2016-02-17
ES2498521B1 (es) 2015-08-18

Similar Documents

Publication Publication Date Title
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
MY196173A (en) Cot Modulators And Methods Of Use Thereof
PH12016500722A1 (en) Bromodomain inhibitors
MY189601A (en) Treatment of beta-thalassemia using actrii ligand traps
MY188934A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
GEP201706725B (en) Compounds and compositions as inhibitors of mek
NZ719169A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
MY179605A (en) Use of benzimidazole-proline derivatives
EA201790276A1 (ru) Новые имидазопиридазиновые соединения и их применение
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
PH12017502021A1 (en) Cyclopropane carboxylic acid derivatives and pharmaceutical uses thereof
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201790315A1 (ru) Модуляторы x-рецепторов печени
ES2498521A1 (es) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
MD20180049A2 (ro) Compoziţie farmaceutică
CY1121708T1 (el) Ενωσεις ουριας ινδανυλιου που αναστελλουν την ρ38 map kιναση
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
EA201591860A1 (ru) Усилители водорастворимости на основе гликогена
EP2992885A3 (en) Method for inhibiting a liver disease
ES2501367A2 (es) Método de tratamiento de coccidiosis
RO130546A3 (ro) Unguent pentru tratamentul bolii hemoroidale
ES2499965A1 (es) Procedimiento de síntesis de compuestos homólogos de azanucleósidos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2498521

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150818

FD2A Announcement of lapse in spain

Effective date: 20210915